You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨泰凌醫藥(1011.HK)高開14.59% 就獲授產品商業化許可協議進入後期磋商階段
格隆匯 05-18 09:23
格隆匯5月18日丨泰凌醫藥(1011.HK)高開14.59%,報0.212港元,總市值4億港元。泰凌醫藥公佈,與一間美國註冊成立的臨牀階段生物製藥公司就簽訂許可協議進入後期磋商階段,據此該公司將向公司全資附屬公司授予許可,將若干單克隆抗體產品商業化,雙方正在敲定許可協議的條款。公司亦與一家中國公司就訂立出售協議進入後期磋商階段,據此公司全資附屬公司將有條件同意出售,及買方有條件同意購買有關附屬公司若干有形資產,雙方正在敲定出售協議的條款。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account